

## LETTER TO THE EDITOR

# Psychopathological comorbidity in patients with chronic pain and the need for greater collaboration between specialists.

LORENZO PELIZZA<sup>1</sup>, SIMONA PUPO<sup>2</sup>, CAMILLA BARBI<sup>3</sup>, MARIKA ALESSIA INCARDONA<sup>4</sup>, GIOVANNI MUSETTI<sup>2</sup>, MARCO MENCHETTI<sup>1</sup>

<sup>1</sup>Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum Università degli Studi di Bologna, Bologna, Italy; <sup>2</sup>Pain Therapy Service, Department of Medicine and Surgery, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; <sup>3</sup>Department of Medicine, Surgery and Morphological Sciences, Università degli Studi di Modena e Reggio Emilia, Modena, Italy; <sup>4</sup>Department of Humanistic, Social and Cultural Disciplines, Università degli Studi di Parma, Parma, Italy.

## To the Editor,

*Mental disorders and chronic pain* are two leading causes of *disability* worldwide and often *co-occur*, although with considerable variance, due to inconsistent methods of assessing psychopathology (self-reports versus standardized interviews) (1). A deeper understanding of psychopathology in chronic pain (a putative predictor of poor prognosis) can thus improve treatment response and outcomes (2). Conversely, failing to detect psychopathology can lead to increase the risk of undertreatment and pain medication abuse (3). Mental disorders are now easily accessible to pharmacotherapy/psychotherapy, potentially decreasing the persistence of pain (4). Despite this evidence of comorbidity, psychopathology in chronic pain remains partially under-diagnosed/under-treated, suggesting poor collaboration between pain therapy and psychiatric services (5). In a recent survey exploring the prevalence

of current psychiatric comorbidity in 172 chronic pain patients during their first consultation within the pain therapy service of the *Parma University Hospital* (Northern Italy) (6), we reported that one-fifth of our participants had a comorbid mental disorder currently diagnosed and treated by mental health professionals (particularly major depressive disorder), and another 7 patients were taken psychotropic drug exclusively to treat current psychopathology. This subgroup also had longer duration of pain, higher prevalences of unemployment and fixed-dose analgesia, and greater severity levels of current pain and interference with daily functioning (Table 1). Notably, approximately 52% of participants with no currently confirmed comorbid psychopathology exceeded at least one of the cut-off scores for the presence of a clinically relevant psychiatric syndrome. Correlation analyses further confirmed these statistically significant associations, also after checking for duration of chronic pain (Table 2).



Received: 8 October 2025 | Accepted: 8 November 2025

**Correspondence:** Lorenzo Pelizza / c/o Istituto di Psichiatria "Paolo Ottonello", Viale Pepoli 5, 40106 Bologna (BO), Italy / E-mail: lorenzo.pelizza@unibo.it

**Table 1.** Sociodemographic and clinical features in the two subgroups.

Variables	PSY+ (n=31)	PSY- (n=141)	X <sup>2</sup> /U	P
Gender (females)	22 (71.0%)	91 (64.5%)	.466	.495
Age at entry (in years)	46.8±9.37	47.5±10.50	1986	.427
Years of education	12.60±3.22	13.10±3.20	2006	.461
Civil status (single)	12 (38.7%)	26 (18.4%)	6.360	.118
Living status (alone)	9 (29.0%)	21 (14.9%)	4.840	.163
Unemployment	9 (29.0%)	17 (12.1%)	13.019	<b>.005</b>
Nationality (Italian)	30 (96.8%)	129 (91.5%)	1.020	.467
Duration of chronic pain (in months)	82.90±92.80	52.80±119.00	1448	<b>.003</b>
ICD-11 primary chronic pain	24 (77.4%)	127 (90.1%)	3.790	.091
Fixed-dose analgesic treatment	24 (77.4%)	72 (51.1%)	7.160	<b>.032</b>
<i>BPI Pain items</i>				
BPI-3: Worst pain in the last 24 hours	7.94±1.94	7.13±2.15	1713	.065
BPI-4: Least pain in the last 24 hours	5.00±2.57	4.49±2.36	1905	.261
BPI-5: Average pain in the last 24 hours	6.97±1.45	6.04±2.13	1587	<b>.015</b>
BPI-6: Current pain	6.77±1.87	5.60±2.61	1577	<b>.014</b>
Mean severity score	7.49±1.75	6.35±2.37	1556	<b>.012</b>
BPI-8: Percentage of pain relief in the last 24 hours	34.52±30.86	36.45±27.00	2026	.521
<i>BPI Interference items</i>				
BPI-9A: General activity	8.35±1.87	7.22±2.57	1602	<b>.018</b>
BPI-9B: Mood	7.35±3.05	6.98±2.96	1936	.314
BPI-9C: Walking ability	6.97±3.14	5.79±3.20	1661	<b>.036</b>
BPI-9D: Normal work (including housework)	7.90±2.65	7.13±2.77	1771	.094
BPI-9E: Social relationships	6.81±2.94	5.18±3.50	1582	<b>.015</b>
BPI-9F: Sleep	7.52±2.89	6.48±3.22	1734	.069
BPI-9G: Enjoyment of life	7.55±2.93	5.67±3.63	1502	<b>.006</b>
Mean activity interference score	7.74±1.97	6.71±2.35	1608	<b>.021</b>
Mean affective interference score	7.24±2.42	5.94±2.98	1640	<b>.030</b>
Mean interference score	7.49±1.75	6.35±2.37	1556	<b>.012</b>
<i>MCMI-III (cut-off score of ≥ 75: presence of disorder)</i>				
At least one cut-off score of ≥ 75	25 (80.6%)	73 (51.8%)	8.640	<b>.003</b>
			28.200	<b>.001</b>
A-Anxiety	9 (29.0%)	32 (22.7%)	[.749]	
H-Somatoform disorder	4 (12.9%)	21 (14.9%)	[.285]	
D-Dysthymic disorder	0 (0.0%)	4 (2.8%)	[-.948]	
T-Drug dependence	0 (0.0%)	1 (0.7%)	[-.470]	
SS-Thought disorder	1 (3.2%)	1 (0.7%)	[1.183]	
CC-Major depression	9 (29.0%)	5 (3.5%)	[4.699]	
PP-Delusional disorder	2 (6.5%)	9 (6.4%)	[.014]	
Absence of disorder	6 (19.4%)	68 (48.2%)	[2.939]	

*Abbreviations:* PSY+ = Participants with psychiatric comorbidity; PSY- = participants without psychiatric comorbidity; BPI = Brief Pain Inventory; MCMI-III = Millon Clinical Multiaxial Inventory. Frequencies (and percentages), mean (±standard deviation), Chi-square test (X<sup>2</sup>) and Mann-Whitney test (U) values are reported. Adjusted standardized residuals are in square brackets. Statistically significant p values are bold. Bonferroni's corrected p values are reported.

Although lower than that observed in previous research (2-4), our prevalence of comorbid psychopathology suggests the importance of not overlooking and appropriately identifying and treating mental

disorders in close collaboration with mental health professionals. Because it is associated with worse outcomes, appropriate treatment of this comorbidity can improve clinical and functional recovery in chronic

**Table 2.** Correlation analyses between psychiatric comorbidity and other statistically significant clinical parameters, also after controlling for duration of chronic pain.

Variables	$\rho$ (p)	After controlling for duration of chronic pain $\rho$ (p)
Unemployment	.182 (.011)	.187 (.014)
Fixed-dose analgesic treatment	.197 (.009)	.194 (.010)
<i>BPI scores</i>		
Mean severity score	.185 (.015)	.167 (.028)
Mean interference score	.189 (.012)	.165 (.030)
<i>MCMI-III (cut-off score <math>\geq 75</math>: presence of disorder)</i>		
At least one cut-off score $\geq 75$	.239 (.002)	.210 (.006)

*Abbreviations:*  $\rho$  = Spearman’s rho coefficient; p = statistical significance; BPI = Brief Pain Inventory; MCMI-III = Millon Clinical Multiaxial Inventory, III edition. Statistically significant p values are in bold.

pain. Psychiatrists should also be made aware of this. Indeed, chronic pain is not a key component of clinical psychiatry and is not formally taught (7). Furthermore, many psychiatrists continue to mistakenly consider psychopathology in chronic pain as secondary to undiagnosed organic illnesses (8). Finally, pain clinicians are often reluctant to cede professional territory to mental health (9). These factors impede the involvement of mental health professionals in pain management and weaken constructive interdisciplinary cooperation. Our results also significantly highlight that a large proportion of participants without a confirmed psychiatric diagnosis currently suffer from severe psychopathology without receiving an appropriate psychiatric diagnosis/treatment. The stable inclusion of mental health operators in multidisciplinary chronic pain teams could fill this gap, promote more appropriate interventions, and improve pain outcomes by offering relevant psychopathological assessments, psychotherapy, and continuous clinical/pharmacological monitoring. Moreover, our findings support the idea that some patients with chronic pain and comorbid psychopathology may be treated pharmacologically only by general practitioners, without being diagnosed by specialists and without accessing mental healthcare services, with an increased risk of treatment inappropriateness. In conclusion, only a *minority* of individuals with chronic pain are likely treated and monitored for their current psychopathology. Because this comorbidity complicates pain treatment and outcomes, unmasking undetected mental disorders helps improve

prognosis in chronic pain. The continued involvement of mental health professionals within *multidisciplinary* chronic pain teams is warranted, as is the development of specific processes/procedures that involve both psychiatric and chronic pain services.

**Authors’ Contribution:** All authors wrote, read, and approved the final version of the manuscript.

**Ethical Standard:** In the cited study, all participants gave written informed consent for the inclusion in the research. Local ethical approvals were obtained for the study (AVEN Ethics Committee protocol no. 20841/2023). Finally, the investigation was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.

**Conflict of Interest:** Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

**Declaration on the Use of AI:** None.

**References**

1. Burke ALJ, Mathias JL, Denson LA. Psychological functioning of people living with chronic pain: a meta-analytic review. *Br J Clin Psychol.* 2015;54:345-60. doi: 10.1111/bjc.12078.

2. Themelis K, Gillett JL, Karadag P, et al. Mental defeat and suicidality in chronic pain: a prospective analysis. *J Pain*. 2023;24:2079-92. doi: 10.1016/j.jpain.2023.06.017.
3. Rouch I, Strippoli MF, Dorey JM, et al. Psychiatric disorders, personality traits, and childhood traumatic events predicting incidence and persistence of chronic pain: results from the CoLaus-PsyCoLaus study. *Pain*. 2023;164:2084-92. doi: 10.1097/j.pain.0000000000002912.
4. Vogt S, Pfau G, Vielhaber S, Haghikia A, Hachenberg T, Brinkers M. Long-term opioid therapy and mental health comorbidity in patients with chronic pain. *Pain Med*. 2023;24:837-45. doi: 10.1093/pm/pnad004.
5. Scholten S, Glombiewski JA. Enhancing psychological assessment and treatment of chronic pain: a research agenda for personalized and process-based approaches. *Curr Opin Psychol*. 2025;62:101958. doi: 10.1016/j.copsyc.2024.101958.
6. Pupo S, Barbi C, Sivelli S, Manferdini E, Musetti G, Pelizza L. Psychopathology and personality in chronic pain: the P3 study. *J Anesth Analg Crit Care*. 2024;4:A138. doi: 10.1186/s44158-024-00192-0.
7. Bass C, Yates G. Why does psychiatry continue to ignore the problem of chronic pain? *Lancet Psychiatry*. 2019;6:10-2. doi: 10.1016/S2215-0366(18)30391-2.
8. Elman I, Zubieta JK, Borsook D. The missing p in psychiatric training: why it is important to teach pain to psychiatrists. *Arch Gen Psychiatry*. 2011;68:12-20. doi: 10.1001/archgenpsychiatry.2010.174.
9. Bestall J, Siddiqi N, Heywood-Everett S, et al. New models of care: a liaison psychiatry service for medically unexplained symptoms and frequent attenders in primary care. *BJPsych Bull*. 2017;41:340-4. doi: 10.1192/pb.bp.116.055731.

---

**Copyright:** The Author(s), 2026. Licensee Mattioli 1885, Fidenza, Italy. This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License (CC BY-NC-4.0).

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in this article are solely those of the author(s) and contributor(s) and do not necessarily reflect those of their affiliated organizations, the publisher, the editors or the reviewers. The publisher and the editors disclaim any responsibility for injury to people or property resulting from any ideas, methods, instructions or products mentioned in the content. Any product that may be evaluated in this article, or claim made by its manufacturer, is not guaranteed or endorsed by the publisher.